Tirzepatide: third-party lab results, COA-2026-9422
- Compound
- Tirzepatide
- Certificate
- COA-2026-9422
- Purity
- 99.20%
- Method
- HPLC (RP-HPLC / HPLC-RTM)
- Identity
- Confirmed
- Testing lab
- Titreon Analytical
- Quality system
- Aligned to ISO/IEC 17025:2017
- Lot
- TZ-2605
- CAS
- 2023788-19-2
- Issued
- 2026-07-02
Mass spec: Deconvoluted neutral mass 4813.5 Da, matches theoretical 4813.5 Da, identity confirmed by LC-MS, ESI positive.
| Test | Result |
|---|---|
| Peptide Purity (HPLC) | 99.20% (spec >= 95.0%), PASS |
| Net Peptide Content | 20.10 mg (report only), REPORTED |
| Identity (HPLC-RTM) | Tirzepatide, Confirmed, PASS |
| Fentanyl Screen | Not Detected (immunoassay, 50 ng/mL), PASS |
| Water (Karl Fischer, USP 921) | 3.80% w/w (spec NMT 8.0% w/w), PASS |
| Counterion (acetate, ion chromatography) | 7.90% w/w (report only), REPORTED |
| Residual Solvents (TFA, USP 467) | Not Detected, PASS |
| Gross Fill Weight (gravimetric) | 23.38 mg (report only), REPORTED |
| Arsenic (As, ICP-MS) | Not Detected (spec NMT 1.5 ppm), PASS |
| Cadmium (Cd, ICP-MS) | Not Detected (spec NMT 0.5 ppm), PASS |
| Chromium (Cr, ICP-MS) | Not Detected (spec NMT 10 ppm), PASS |
| Mercury (Hg, ICP-MS) | Not Detected (spec NMT 1.5 ppm), PASS |
| Lead (Pb, ICP-MS) | Not Detected (spec NMT 1 ppm), PASS |
| Sterility (USP 71) | No Growth, PASS |
| Bioburden (USP 61) | < 1 CFU/mL (spec < 10 CFU/mL), PASS |
| Bacterial Endotoxin (USP 85) | < 0.5 EU/vial (spec NMT 5 EU/mL), PASS |
The Aion Tirzepatide batch was tested at 99.20 percent purity by HPLC, with identity confirmed by mass spectrometry. The certificate is issued by Titreon Analytical, which operates a quality system aligned to ISO/IEC 17025:2017, under certificate COA-2026-9422.
Beyond purity, the panel covers identity confirmation (HPLC-RTM), a fentanyl screen (not detected), water content by Karl Fischer, residual solvents, five heavy metals by ICP-MS (all not detected), sterility, bioburden, and bacterial endotoxin. Every specification passed.
Purity is measured by reversed-phase HPLC. Mass spec (LC-MS, ESI positive) returned a deconvoluted neutral mass of 4813.5 Da, matching the theoretical mass of tirzepatide, confirming identity independently of the purity assay.
This certificate documents laboratory identity and purity testing only. The compound is sold for research use only, is not approved by the FDA for human use, and nothing here is medical advice.